reports
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Da...
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an...
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in Fir...
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard of care (SoC) regimens (FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line RAS-mutated metastatic ...
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase ...
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis (MF) in an ...
Progress Software Releases 2025 Corporate Social Responsibility Report...
Progress Software Releases 2025 Corporate Social Responsibility Report, Underscoring Global Commitment to Giving Back Report showcases a people‑first culture, measurable global community impact and continued advancements toward long‑term sustainability goals that contributed to multiple Best Workplace honors BURLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PRGS), the trusted provider of AI-powered digital experience and infrastructure software, today announced the release of its 2025 Corporate Social Responsibility (CSR) report. The annual report highlights the company’s d...
Egeyapi Avrupa Gayrimenkul Yatirim Ortakligi A.S.: 1 director
A director at Egeyapi Avrupa Gayrimenkul Yatirim Ortakligi A.S. sold 8,862,890 shares at 31.690TRY and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) ...
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company’s core investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of locally advanced or metastatic ga...
Form 8.3 - Picton Property Income Limited
Form 8.3 - Picton Property Income Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities thi...
Correction: Form 8.3 - LondonMetric Property Plc & Schroder REIT Limit...
Correction: Form 8.3 - LondonMetric Property Plc & Schroder REIT Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation...
Form 8.3 - LondonMetric Property Plc & Schroder REIT Limited
Form 8.3 - LondonMetric Property Plc & Schroder REIT Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose rele...
Form 8.3 - Advanced Medical Solutions Group
Form 8.3 - Advanced Medical Solutions Group 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities t...
Advanced Chemical Industries Ltd: 1 director
A director at Advanced Chemical Industries Ltd bought 302,000 shares at 0.000BDT and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Holley Launches High-Performance Car Care in Partnership with Malco Au...
Holley Launches High-Performance Car Care in Partnership with Malco Automotive New six-product lineup advances Holley’s chemicals expansion strategy by entering the recurring-purchase car care category with commercial-grade detailing manufacturer NASHVILLE, Tenn., April 21, 2026 (GLOBE NEWSWIRE) -- Holley, the iconic performance brand behind industry-leading EFI, carburetion and engine swap solutions, in the (NYSE: HLLY) portfolio, today announced the launch of Holley High-Performance Car Care, a new line of automotive detailing products developed in partnership with Malco Automotive....
Assetwise Public Company Ltd: 1 director
A director at Assetwise Public Company Ltd bought 3,565,800 shares at 7.000THB and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
International Tower Hill Mines Ltd: 1 director
A director at International Tower Hill Mines Ltd bought 4,913,665 shares at 2.560USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Koray Gayrimenkul Yatirim Ortakligi A.S.: 1 director
A director at Koray Gayrimenkul Yatirim Ortakligi A.S. sold 10,000,000 shares at 11.850TRY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Seef Properties: 1 director
A director at Seef Properties bought 2,753,973 shares at 0.000BHD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Johnson & Johnson (JNJ) Forecast: Buyers Should Enter Between 227.8 - ...
Johnson & Johnson (JNJ) engages in research & development, manufacture & sale of range of products in the healthcare sector worldwide. It operates through Innovative Medicine & MedTech. It comes under Healthcare sector & trades as “JNJ” at NYSE.
SoundHound AI To Acquire LivePerson, Combining Proprietary Voice Agent...
SoundHound AI To Acquire LivePerson, Combining Proprietary Voice Agentic AI and Digital Messaging to Create a World Leading End-to-End Omnichannel Conversational AI Platform Transaction results in one of the most comprehensive enterprise customer footprints in the conversational AI sector, including 25 of the Fortune 100Combined company expects a $500M revenue opportunity, accelerated path to profitability, strong balance sheet, and no debt SANTA CLARA, Calif. and NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversationa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.